Abstract
β-adrenergic agonists and especially β-2 adrenergic agonists are generally prescribed for all asthmatics as a backup medication to anti-inflammatory therapy or, in the case of exercise-induced asthma, as the primary drug. Technological advances have led to the development of increased β-2-specific adrenergic agonists of longer duration of action. The effectiveness of β-adrenergic agonists in treating asthma is indisputable. However, the very effectiveness of these drugs causes problems of overuse and consequent side effects raising such issues as whether other drugs or other parameters should be preferentially utilized.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Suggested Reading
AAAAI Committee on Drugs, Position statement: safety and appropriate use of salmeterol in the treatment of asthma J. Allerg. Clin. Immunol. 1996; 98: 475–480.
Blauw GJ, Westendorp RGJ. Asthma deaths in New Zealand: whodunnit? Commentary. Lancet 1995; 345: 2,3.
Drugs for asthma. The Med Let 1995; 37: 1–4.
Furukawa CT, Kemp JP, Simons FER, Tinkelman DG. The proper role of 132-adrenergic agaonists in the treatment of children with asthma. Pediatrics 1992; 90: 639–640.
Gibson P, Henry D, Francis L, Chuickshank D, Dupen F, Higginbotham N, Henry R, Sutherland D, Association between availability of non-prescription beta 2 against inhalers and under treatment of asthma. Br Med J 1993; 306: 1514–1518.
McFadden ER. Perspectives in (32-agonist therapy: Vox clamantis in deserto vel lux tenebris? JAllergy Clin Immunol 1995; 95: 641–651.
Mullen M, Mullen B, Carey M. The association between 13-agonist use and death from asthma. JAMA 1993; 270: 1842–1845.
Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, Blais L, McNutt M, Buist AS, Spitzer WO. A cohort analysis of excess mortality in asthma and the use of inhaled (3-agonists. Am J Respir Crit Care Med 1994; 149: 604–610.
Taylor DR, Sears MR. Regular beta-adrenergic atonists. Evidence, not reassurance, is what is needed. Chest 1994; 106: 552–559.
Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, Lake DC, Yates DM, Lucas MK, Li Q. Regular inhaled 13 agonist in asthma: effects on exacerbations and lung function. Thorax 1993; 48: 134–138.
Wahedna I, Wong CS, Wisniewski AFZ, Pavord AD, Tattersfield AE. Asthma control during and after cessation of regular beta-2 agonist treatment. Am Rev Respir Dis 1993; 148: 707–712.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Furukawa, C.T. (1997). β-Adrenergic Agonists. In: Lieberman, P., Anderson, J.A. (eds) Allergic Diseases. Current Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4757-2591-9_17
Download citation
DOI: https://doi.org/10.1007/978-1-4757-2591-9_17
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-2593-3
Online ISBN: 978-1-4757-2591-9
eBook Packages: Springer Book Archive